Ubs Group Ag Viking Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 328,959 shares of VKTX stock, worth $13.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

328,959

Previous 359,382 8.47%

Holding current value

$13.4 Million

Previous $19.1 Million 9.32%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$49.84 - $70.47 $1.52 Million - $2.14 Million	-30,423 Reduced 8.47%	328,959 $20.8 Million
Q2 2024 Aug 13, 2024	BUY	$47.39 - $80.2 $4.04 Million - $6.84 Million	85,326 Added 31.13%	359,382 $19.1 Million
Q1 2024 May 13, 2024	SELL	$17.4 - $94.5 $1.14 Million - $6.21 Million	-65,670 Reduced 19.33%	274,056 $22.5 Million
Q4 2023 Feb 09, 2024	BUY	$9.24 - $19.64 $1.81 Million - $3.85 Million	196,015 Added 136.4%	339,726 $6.32 Million
Q3 2023 Nov 09, 2023	SELL	$10.92 - $16.0 $145,749 - $213,552	-13,347 Reduced 8.5%	143,711 $1.59 Million
Q2 2023 Aug 11, 2023	SELL	$14.84 - $24.79 $447,485 - $747,517	-30,154 Reduced 16.11%	157,058 $2.55 Million
Q1 2023 May 12, 2023	BUY	$8.08 - $17.33 $1.14 Million - $2.45 Million	141,164 Added 306.56%	187,212 $3.12 Million
Q4 2022 Feb 08, 2023	BUY	$2.72 - $9.4 $13,548 - $46,821	4,981 Added 12.13%	46,048 $432,000
Q3 2022 Nov 10, 2022	SELL	$2.55 - $3.89 $3,156 - $4,815	-1,238 Reduced 2.93%	41,067 $112,000
Q2 2022 Aug 10, 2022	SELL	$2.11 - $3.15 $71,860 - $107,279	-34,057 Reduced 44.6%	42,305 $122,000
Q1 2022 May 16, 2022	SELL	$3.0 - $4.88 $767,397 - $1.25 Million	-255,799 Reduced 77.01%	76,362 $229,000
Q4 2021 Feb 14, 2022	BUY	$4.6 - $6.72 $282,196 - $412,251	61,347 Added 22.65%	332,161 $1.53 Million
Q3 2021 Nov 15, 2021	BUY	$5.58 - $7.04 $573,540 - $723,606	102,785 Added 61.17%	270,814 $1.7 Million
Q2 2021 Aug 13, 2021	SELL	$5.19 - $6.73 $713,962 - $925,812	-137,565 Reduced 45.02%	168,029 $1.01 Million
Q1 2021 May 12, 2021	BUY	$5.74 - $9.67 $1.27 Million - $2.13 Million	220,695 Added 259.95%	305,594 $1.93 Million
Q4 2020 Feb 11, 2021	SELL	$5.3 - $6.71 $1.33 Million - $1.69 Million	-251,568 Reduced 74.77%	84,899 $478,000
Q3 2020 Nov 12, 2020	BUY	$5.73 - $8.11 $33,153 - $46,924	5,786 Added 1.75%	336,467 $1.96 Million
Q2 2020 Jul 31, 2020	SELL	$4.35 - $8.08 $260,678 - $484,202	-59,926 Reduced 15.34%	330,681 $2.39 Million
Q1 2020 May 01, 2020	SELL	$3.45 - $7.95 $66,333 - $152,854	-19,227 Reduced 4.69%	390,607 $1.83 Million
Q4 2019 Feb 14, 2020	SELL	$6.38 - $8.73 $1.08 Million - $1.48 Million	-169,656 Reduced 29.28%	409,834 $3.29 Million
Q3 2019 Nov 14, 2019	BUY	$6.55 - $8.6 $100,424 - $131,855	15,332 Added 2.72%	579,490 $3.99 Million
Q2 2019 Aug 14, 2019	BUY	$7.67 - $10.63 $2.24 Million - $3.1 Million	291,756 Added 107.1%	564,158 $4.68 Million
Q1 2019 May 14, 2019	SELL	$7.58 - $9.94 $1.79 Million - $2.35 Million	-236,570 Reduced 46.48%	272,402 $2.71 Million
Q4 2018 Feb 14, 2019	BUY	$7.16 - $16.21 $2.17 Million - $4.91 Million	302,815 Added 146.89%	508,972 $3.89 Million
Q3 2018 Nov 14, 2018	BUY	$9.7 - $19.65 $1.2 Million - $2.44 Million	123,956 Added 150.8%	206,157 $3.59 Million
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $73,223 - $240,429	18,872 Added 29.8%	82,201 $780,000
Q1 2018 May 15, 2018	BUY	$4.11 - $6.93 $219,182 - $369,569	53,329 Added 533.29%	63,329 $277,000
Q4 2017 Feb 14, 2018	BUY	$1.74 - $4.34 $17,400 - $43,400	10,000 New	10,000 $41,000
Q2 2017 Aug 14, 2017	SELL	N/A	-4,506 Closed	0 $0
Q1 2017 Nov 14, 2017	BUY	N/A	4,506	4,506 $7,000

Others Institutions Holding VKTX

# of Institutions

474

Shares Held

64.6M

Call Options Held

5.72M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.11B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account